Radimmune Therapeutics, Inc.

UEI
EZJ3T8AFYMC3
CAGE
7PHL6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Other NAICS codes in SAM.gov
SAM.gov registration date
Website
radimmune.com
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Radioimmunotherapy of melanoma with novel LGG to melanin HHSN261201600017C National Cancer Institute (NIH) $295,782

Quick answers

Is Radimmune Therapeutics, Inc. registered in SAM.gov?

Radimmune Therapeutics, Inc.'s SAM.gov registration expired on July 1, 2022.

What is Radimmune Therapeutics, Inc.'s most recent federal award?

Radimmune Therapeutics, Inc.'s most recent federal contract award is Radioimmunotherapy of melanoma with novel LGG to melanin (HHSN261201600017C), from National Cancer Institute (NIH), on September 19, 2016.

On GovTribe

See Radimmune Therapeutics, Inc.'s full federal record

  • Federal contract awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login